Odyssey Therapeutics (United States)

Recent papers from Odyssey Therapeutics (United States)

1. SARM1 is responsible for calpain-dependent dendrite degeneration in mouse hippocampal neuronsJournal of Biological Chemistry · 2024
2. NLRP3 Inhibition Leads to Impaired Mucosal Fibroblast Function in Patients with Inflammatory Bowel DiseasesJournal of Crohn s and Colitis · 2023
3. NLRP3 selectively drives IL-1β secretion by Pseudomonas aeruginosa infected neutrophils and regulates corneal disease severityNature Communications · 2023
4. Human-in-the-loop assisted de novo molecular designJournal of Cheminformatics · 2022
5. Discovery of small molecules that target a tertiary-structured RNAProceedings of the National Academy of Sciences · 2022
6. Mircubactin B rescues the lethal effect of cell wall biosynthesis mutations in Bacillus subtilis2022
7. Ex vivo activated memory T‐Iymphocytes as adoptive cellular therapy of human renal cell tumour targets with potentiation by cis‐diamminedichloroplatinum(II)British Journal of Urology · 1995
8. Adoptive transfer of ex vivo‐activated memory T‐cell subsets with cyclophosphamide provides effective tumor‐specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinomaInternational Journal of Cancer · 1995
9. Ex vivo activated memory t‐lymphocytes as adoptive cellular therapy of human soft‐tissue sarcoma targets with potentiation by Cis‐diamminedichloroplatinum (II)Journal of Surgical Oncology · 1995
10. Adoptive cellular therapy of human breast and colorectal tumor targets using ex vivo activated memory T lymphocytes with potentiation by cis‐diamminedichloroplatinum(II)Journal of Surgical Oncology · 1994